Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anxo Pharmaceutical CoROCO:6677 -0.30%65 EV-to-EBITDA is 22.39 as of Sep. 08, 2026, which is 21% above its 10-year median of 18.55. GuruFocus rates ROCO:6677 with a GF Score™ of 65/100 and a GF Value™ of NT$24.20 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 726 Drug Manufacturers companies, Anxo Pharmaceutical Co ranks worse than 71.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anxo Pharmaceutical Co's enterprise value is NT$1,465.5 Mil.
Anxo Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$65.5 Mil. Therefore, Anxo Pharmaceutical Co's EV-to-EBITDA for today is 22.39.
The historical rank and industry rank for Anxo Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6677'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.54 Med: 18.55 Max: 64.01
Current: 22.39
During the past 13 years, the highest EV-to-EBITDA of Anxo Pharmaceutical Co was 64.01. The lowest was 12.54. And the median was 18.55.
ROCO:6677's EV-to-EBITDA is ranked worse than 71.07% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.75
vs ROCO:6677: 22.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Anxo Pharmaceutical Co (ROCO:6677) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anxo Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Anxo Pharmaceutical Co's share price for today is NT$16.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anxo Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anxo Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Anxo Pharmaceutical Co's EV-to-EBITDA falls into.
Anxo Pharmaceutical Co's current Enterprise Value is NT$1,465.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anxo Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$65.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anxo Pharmaceutical Co (ROCO:6677) has a EV-to-EBITDA of 22.39 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anxo Pharmaceutical Co. This is 21% above median its historical median of 18.55. Over the past decade, Anxo Pharmaceutical Co's EV-to-EBITDA has ranged from 12.54 to 64.01. According to the industry distribution chart, Anxo Pharmaceutical Co ranks #516 out of 726 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is Anxo Pharmaceutical Co's EV-to-EBITDA too high?
Anxo Pharmaceutical Co's current EV-to-EBITDA of 22.39 is 21% above median its 10-year median of 18.55. Over the past 10 years, this metric has ranged from a low of 12.54 to a high of 64.01. The Drug Manufacturers industry median EV-to-EBITDA is 13.75. Anxo Pharmaceutical Co's value of 22.39 is 62.8% above this industry median. Based on the distribution chart, Anxo Pharmaceutical Co ranks #516 out of 726 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anxo Pharmaceutical Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anxo Pharmaceutical Co ranks #516 out of 726 companies for EV-to-EBITDA. This places Anxo Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.75. Anxo Pharmaceutical Co's value of 22.39 is 62.8% above this benchmark. Historically, Anxo Pharmaceutical Co's own EV-to-EBITDA has ranged from 12.54 to 64.01 over the past decade. While the company's 10-year median is 18.55 vs. the industry median of 13.75, Anxo Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.75, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anxo Pharmaceutical Co's current EV-to-EBITDA of 22.39 is 62.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anxo Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anxo Pharmaceutical Co's current EV-to-EBITDA is 22.39, which is 21% above median its own 10-year median of 18.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.20, compared to a current price of NT$16.85 — trading 30.4% below its estimated fair value. The current EV-to-EBITDA is 22.39, which is 21% above median its 10-year median of 18.55 and 62.8% above the Drug Manufacturers industry median of 13.75. Anxo Pharmaceutical Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current EV-to-EBITDA is 22.39 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$16.85 is trading 30.4% below its estimated GF Value™ of NT$24.20.
GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for ROCO:6677:
EV-to-EBITDA: 22.39 (21% above median its 10-year median of 18.55)
GF Value™: NT$24.20 vs. price of NT$16.85 (30.4% below fair value)
Industry Position: 62.8% above the Drug Manufacturers median (#516 of 726)
No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
65GF Score
Get the complete analysis for ROCO:6677
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6677 has been successfully added to your 
